Arrhythmias - Pipeline Review, H1 2017

Date: March 15, 2017
Pages: 47
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A6A02A68210EN
Leaflet:

Download PDF Leaflet

Arrhythmias - Pipeline Review, H1 2017
Arrhythmias - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Pipeline Review, H1 2017, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.

An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arrhythmias - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

REASONS TO BUY
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Arrhythmias - Overview
Arrhythmias - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Arrhythmias - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Arrhythmias - Companies Involved in Therapeutics Development
Allosteros Therapeutics Inc
Cynata Therapeutics Limited
Gilead Sciences Inc
Ono Pharmaceutical Co Ltd
Orion Oyj
SignPath Pharma Inc
Arrhythmias - Drug Profiles
aladorian sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efsevin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eleclazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EU-8120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KN-93 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
landiolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-201A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORM-10103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPP-4040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VKII-86 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Arrhythmias - Dormant Projects
Arrhythmias - Discontinued Products
Arrhythmias - Product Development Milestones
Featured News & Press Releases
May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Arrhythmias, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Arrhythmias - Pipeline by Allosteros Therapeutics Inc, H1 2017
Arrhythmias - Pipeline by Cynata Therapeutics Limited, H1 2017
Arrhythmias - Pipeline by Gilead Sciences Inc, H1 2017
Arrhythmias - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Arrhythmias - Pipeline by Orion Oyj, H1 2017
Arrhythmias - Pipeline by SignPath Pharma Inc, H1 2017
Arrhythmias - Dormant Projects, H1 2017
Arrhythmias - Discontinued Products, H1 2017

LIST OF FIGURES

Number of Products under Development for Arrhythmias, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Allosteros Therapeutics Inc
Cynata Therapeutics Limited
Gilead Sciences Inc
Ono Pharmaceutical Co Ltd
Orion Oyj
SignPath Pharma Inc
Skip to top


Arrhythmias - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 55 pages
Axillary Hyperhidrosis - Pipeline Review, H1 2017 US$ 2,000.00 Apr, 2017 · 53 pages
Polycythemia Vera - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 68 pages
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016 US$ 3,500.00 Jun, 2016 · 59 pages

Ask Your Question

Arrhythmias - Pipeline Review, H1 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: